Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;59(4):477-483.
doi: 10.1111/ajo.12982. Epub 2019 May 22.

Prenatal screening for pre-eclampsia: Frequently asked questions

Dagmar Wertaschnigg  1   2 , Maya Reddy  1   3 , Ben W J Mol  1   3 , Daniel L Rolnik  1   3 , Fabricio da Silva Costa  1   4
Affiliations
Review

Prenatal screening for pre-eclampsia: Frequently asked questions

Dagmar Wertaschnigg et al. Aust N Z J Obstet Gynaecol. 2019 Aug.

Abstract

The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

Keywords: aspirin; hypertensive disorders in pregnancy; pre-eclampsia; prevention; screening.

PubMed Disclaimer

References

    1. Lowe SA, Bowyer L, Lust K et al The SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol 2015; 55: 11–16. - PubMed
    1. Askie LM, Duley L, Henderson‐Smart DJ et al Antiplatelet agents for prevention of pre‐eclampsia: a meta‐analysis of individual patient data. Lancet 2007; 369: 1791–1798. - PubMed
    1. Bujold E, Roberge S, Lacasse Y et al Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta‐analysis. Obstet Gynecol 2010; 116: 402–414. - PubMed
    1. Tan MY, Syngelaki A, Poon LC et al Screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Ultrasound Obstet Gynecol 2018; 52: 186–195. - PubMed
    1. O'Gorman N, Wright D, Poon LC et al Multicenter screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017; 49: 756–760. - PubMed

Publication types